| Year |
Citation |
Score |
| 2014 |
Rizzo P, Mele D, Caliceti C, Pannella M, Fortini C, Clementz AG, Morelli MB, Aquila G, Ameri P, Ferrari R. The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors. Frontiers in Oncology. 4: 384. PMID 25629006 DOI: 10.3389/fonc.2014.00384 |
0.454 |
|
| 2011 |
Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer. 105: 796-806. PMID 21847123 DOI: 10.1038/Bjc.2011.321 |
0.684 |
|
| 2011 |
Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Research : Bcr. 13: R63. PMID 21679465 DOI: 10.1186/Bcr2900 |
0.708 |
|
| 2011 |
Pandya K, Meeke K, Rogowski A, Clementz A, Osipo C. Abstract 2553: Inhibition of γ-secretase in combination with Lapatinib induces tumor regressionin vivo Cancer Research. 71: 2553-2553. DOI: 10.1158/1538-7445.Am2011-2553 |
0.672 |
|
| 2010 |
Clementz AG, Rizzo P, Miele L, Osipo C. Abstract 3918: PEA3 is a novel transcriptional activator of Notch-1 and Notch-4 in breast cancer: Opportunity for a new combination strategy Cancer Research. 70: 3918-3918. DOI: 10.1158/1538-7445.Am10-3918 |
0.749 |
|
| 2009 |
Clementz AG, Osipo C. Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I? Breast Cancer Research : Bcr. 11: 110. PMID 19849815 DOI: 10.1186/Bcr2407 |
0.727 |
|
| 2008 |
Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 27: 5019-32. PMID 18469855 DOI: 10.1038/Onc.2008.149 |
0.732 |
|
| Show low-probability matches. |